MA31624B1 - Utilisation de l'urate oxydase pour le traitement ou la prophylaxie de troubles cardiaques ou de leurs sequelles indirectes causes par des evenements d'ischemie ou de reperfusion - Google Patents
Utilisation de l'urate oxydase pour le traitement ou la prophylaxie de troubles cardiaques ou de leurs sequelles indirectes causes par des evenements d'ischemie ou de reperfusionInfo
- Publication number
- MA31624B1 MA31624B1 MA32638A MA32638A MA31624B1 MA 31624 B1 MA31624 B1 MA 31624B1 MA 32638 A MA32638 A MA 32638A MA 32638 A MA32638 A MA 32638A MA 31624 B1 MA31624 B1 MA 31624B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- indirect
- ischemia
- prophylaxis
- cardiac
- Prior art date
Links
- 108010092464 Urate Oxidase Proteins 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 229940005267 urate oxidase Drugs 0.000 title abstract 3
- 230000010410 reperfusion Effects 0.000 title abstract 2
- 208000020446 Cardiac disease Diseases 0.000 title 1
- 208000019622 heart disease Diseases 0.000 title 1
- 208000028867 ischemia Diseases 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 abstract 2
- 238000013146 percutaneous coronary intervention Methods 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 238000007675 cardiac surgery Methods 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 108010084837 rasburicase Proteins 0.000 abstract 1
- 229960000424 rasburicase Drugs 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07291072 | 2007-09-05 | ||
| US1524007P | 2007-12-20 | 2007-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31624B1 true MA31624B1 (fr) | 2010-08-02 |
Family
ID=38713162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32638A MA31624B1 (fr) | 2007-09-05 | 2010-02-22 | Utilisation de l'urate oxydase pour le traitement ou la prophylaxie de troubles cardiaques ou de leurs sequelles indirectes causes par des evenements d'ischemie ou de reperfusion |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20100266567A1 (https=) |
| EP (1) | EP2197550A1 (https=) |
| JP (1) | JP2011509920A (https=) |
| KR (1) | KR20100053609A (https=) |
| CN (1) | CN101801460A (https=) |
| AR (1) | AR068360A1 (https=) |
| AU (1) | AU2008295145B2 (https=) |
| BR (1) | BRPI0816406A2 (https=) |
| CA (1) | CA2697929A1 (https=) |
| CL (1) | CL2008002623A1 (https=) |
| CO (1) | CO6260090A2 (https=) |
| IL (1) | IL204259A (https=) |
| MA (1) | MA31624B1 (https=) |
| MX (1) | MX2010001976A (https=) |
| MY (1) | MY183770A (https=) |
| NZ (1) | NZ583635A (https=) |
| PA (1) | PA8794801A1 (https=) |
| PE (1) | PE20090642A1 (https=) |
| TW (1) | TW200927929A (https=) |
| UY (1) | UY31320A1 (https=) |
| WO (1) | WO2009030373A1 (https=) |
| ZA (1) | ZA201000774B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5114972A (en) * | 1990-07-30 | 1992-05-19 | Tsuyoshi Ohnishi | Synthesis and uses of new ascorbic acid derivatives which have anti-oxidant and anti-cancer activities |
| JP2004517804A (ja) * | 2000-06-28 | 2004-06-17 | メルク・アンド・カンパニー・インコーポレーテッド | 心臓血管病の治療法 |
| AU2003275160A1 (en) * | 2002-09-20 | 2004-04-08 | Oregon Health And Science University | Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries |
| ES2567634T3 (es) * | 2004-02-09 | 2016-04-25 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina |
| WO2005099758A2 (en) * | 2004-04-17 | 2005-10-27 | The Board Of Trustees The Leland Standford Junior University | Injectable bioartificial tissue matrix |
| US20070197512A1 (en) * | 2006-01-27 | 2007-08-23 | Japan Tobacco Inc. | Carboxylic Acid Compounds and Use Thereof |
-
2008
- 2008-08-20 WO PCT/EP2008/006858 patent/WO2009030373A1/en not_active Ceased
- 2008-08-20 KR KR1020107004878A patent/KR20100053609A/ko not_active Ceased
- 2008-08-20 EP EP08785655A patent/EP2197550A1/en not_active Withdrawn
- 2008-08-20 JP JP2010523299A patent/JP2011509920A/ja active Pending
- 2008-08-20 CA CA2697929A patent/CA2697929A1/en not_active Abandoned
- 2008-08-20 CN CN200880105379A patent/CN101801460A/zh active Pending
- 2008-08-20 AU AU2008295145A patent/AU2008295145B2/en not_active Ceased
- 2008-08-20 BR BRPI0816406A patent/BRPI0816406A2/pt not_active IP Right Cessation
- 2008-08-20 NZ NZ583635A patent/NZ583635A/en not_active IP Right Cessation
- 2008-08-20 MX MX2010001976A patent/MX2010001976A/es active IP Right Grant
- 2008-08-20 MY MYPI2010000585A patent/MY183770A/en unknown
- 2008-09-03 TW TW097133674A patent/TW200927929A/zh unknown
- 2008-09-03 UY UY31320A patent/UY31320A1/es not_active Application Discontinuation
- 2008-09-03 PE PE2008001545A patent/PE20090642A1/es not_active Application Discontinuation
- 2008-09-03 AR ARP080103828A patent/AR068360A1/es not_active Application Discontinuation
- 2008-09-03 PA PA20088794801A patent/PA8794801A1/es unknown
- 2008-09-04 CL CL2008002623A patent/CL2008002623A1/es unknown
-
2010
- 2010-02-02 ZA ZA2010/00774A patent/ZA201000774B/en unknown
- 2010-02-22 MA MA32638A patent/MA31624B1/fr unknown
- 2010-02-24 CO CO10021841A patent/CO6260090A2/es not_active Application Discontinuation
- 2010-03-01 US US12/715,061 patent/US20100266567A1/en not_active Abandoned
- 2010-03-02 IL IL204259A patent/IL204259A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200927929A (en) | 2009-07-01 |
| EP2197550A1 (en) | 2010-06-23 |
| NZ583635A (en) | 2011-06-30 |
| MY183770A (en) | 2021-03-12 |
| CA2697929A1 (en) | 2009-03-12 |
| WO2009030373A1 (en) | 2009-03-12 |
| MX2010001976A (es) | 2010-03-10 |
| PE20090642A1 (es) | 2009-06-18 |
| UY31320A1 (es) | 2009-04-30 |
| AU2008295145B2 (en) | 2013-12-05 |
| RU2010112867A (ru) | 2011-10-10 |
| ZA201000774B (en) | 2011-04-28 |
| PA8794801A1 (es) | 2009-04-23 |
| CO6260090A2 (es) | 2011-03-22 |
| CN101801460A (zh) | 2010-08-11 |
| KR20100053609A (ko) | 2010-05-20 |
| US20100266567A1 (en) | 2010-10-21 |
| BRPI0816406A2 (pt) | 2017-05-16 |
| CL2008002623A1 (es) | 2009-01-16 |
| JP2011509920A (ja) | 2011-03-31 |
| AR068360A1 (es) | 2009-11-11 |
| AU2008295145A1 (en) | 2009-03-12 |
| IL204259A (en) | 2013-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51620B1 (fr) | Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques | |
| EP3986863A4 (en) | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASES | |
| MA30806B1 (fr) | Phosphoindoles enantiomeriquement purs utilisables en tant qu'inhibiteurs du vih | |
| NZ600400A (en) | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | |
| WO2008132138A9 (en) | Derivatives of 4,6-disubstituted aminopyrimidines | |
| MA33772B1 (fr) | Dérivés d'acide carboxylique cyclique substitué par acylamino et leur utilisation en tant qu'agents pharmaceutiques | |
| YU78703A (sh) | Derivati merkaptoacetilamida, postupak za njihovo pripremanje i njihova upotreba | |
| MA32483B1 (fr) | Compose heterocyclique et son utilisation | |
| CA3156303A1 (en) | 5-fluoronicotinamide derivatives and uses thereof | |
| MA30478B1 (fr) | Composition comprenant au moins un alcool aliphatique superieur et un extrait de griffonia simplicifolia. | |
| MA31388B1 (fr) | Utilisation d'un composé i pour prévenir ou traiter une formation de biofilm | |
| MA31624B1 (fr) | Utilisation de l'urate oxydase pour le traitement ou la prophylaxie de troubles cardiaques ou de leurs sequelles indirectes causes par des evenements d'ischemie ou de reperfusion | |
| EP4301132A4 (en) | Rock2 inhibitor for the treatment of viral infection | |
| WO2009005838A3 (en) | Process for the preparation of a non-corrosive base solution and methods of using same | |
| JP2017530954A5 (https=) | ||
| US20090075976A1 (en) | Association between an anti-atherothrombotic and an angiotensin-converting enzyme inhibitor | |
| MA28081A1 (fr) | Nouvelle association d'un anti-atherothrombotique et d'un antiagregant plaquettaire | |
| TH104398B (th) | การใช้ยูเรตออกซิเดสเพื่อการรักษาหรือการป้องกันความผิดปกติหรือผลกระทบทางอ้อมที่ตามมาของหัวใจที่เกิดจากภาวะพร่องเลือดหรือผ่านเลือด | |
| WO2021092703A8 (en) | Methods for using low-dose colchicine after myocardial infarction | |
| JP2010513300A5 (https=) | ||
| EE200300500A (et) | Merkaptoatsetüülamiidi derivaadid, nende valmistamismeetod, farmatseutiline kompositsioon ja selle valmistamismeetod | |
| CA3242496A1 (en) | USE OF INHALATED NITRIC OXIDE (INO) TO TREAT PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH SARCOIDOSIS (PH-SARC) | |
| Vivas et al. | Atrial Fibrillation and Anticoagulation Therapy–Different Race, Different Risk, and Different Management?– | |
| EP3981423A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF DISEASES RELATED TO URIC ACID | |
| FR3128872B1 (fr) | Nouvelles combinaisons synergiques a base de fenm |